C4 Therapeutics Inc's Customers Performance

Name: C4 Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

CCCC

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


CCCC's Source of Revenues		During the corresponding time, C4 Therapeutics Inc recorded a revenue increase by 2.75 % year on year, sequentially revenue grew by 7.95 %. While revenue at the C4 Therapeutics Inc 's corporate clients • List of CCCC Customers

for the same period C4 Therapeutics Inc recorded revenue increase by 2.75 % year on year, sequentially revenue grew by 7.95 %.

• List of CCCC Customers

C4 Therapeutics Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

C4 Therapeutics Inc's Comment on Sales, Marketing and Customers

News about C4 Therapeutics Inc Contracts

C4 Therapeutics and Betta Pharmaceuticals Launch CFT8919 Clinical Trials in Greater China

C4 Therapeutics, a biopharmaceutical company specializing in the development of targeted protein degradation therapies, recently announced the dosing of the first patient in a clinical trial for its investigational drug CFT8919. This event marks a significant milestone not only for C4 Therapeutics but also for its partner, Betta Pharmaceuticals, as they embark on clinical development in Greater China.CFT8919 is designed to target and degrade specific proteins implicated in oncogenic processes, particularly focusing on tumors driven by genetic mutations. The initiation of this clinical trial aims to evaluate the safety, tolerability, and pharmacokinetics of CFT8919 in patients with cancer characterized by t...

C4 Therapeutics Unveils Promising Phase 1 Clinical Data for CFT1946 at ESMO Congress 2024

News C4 Therapeutics, a leader in the development of targeted protein degradation therapies, has announced its plans to present preliminary clinical data from the Phase 1 monotherapy trial of CFT1946 at the upcoming European Society for Medical Oncology (ESMO) Congress 2024. The announcement comes with the release of an abstract that showcases a favorable safety profile along with early evidence of anti-tumor activity associated with CFT1946.The ESMO Congress, one of the most prestigious events for oncology professionals, will take place from insert date in insert location. CFT1946 is designed to selectively degrade proteins that drive cancer progression, making it a potentially groundbreaking treatment for...

Revolutionizing Cancer Treatment: C4 Therapeutics and Merck Collaborate on Innovative DACsAlternatively:Pioneering Collaborative Efforts in Oncology: C4 Therapeutics and Merck's Pursuit of Targeted Cancer Therapies

:
In a significant step forward for the field of oncology research, C4 Therapeutics has recently announced a strategic license and research collaboration with Merck. The partnership aims to explore the development of Degrader-Antibody Conjugates (DACs) for targeted treatment of cancers. With an initial focus on one oncology target, exclusive to the collaboration, Merck also holds the option to pursue three additional oncology targets. This collaboration holds tremendous potential for both C4 Therapeutics and Merck, potentially revolutionizing cancer treatment options.
Outline of Facts:
1. C4 Therapeutics has partnered with Merck to establish a license and research collaboration.
2. The c...

CCCC's Stock Performance relative to it's Customers

CCCC's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
C4 Therapeutics Inc	443.06	34.86	-103.80	104
SUBTOTAL	0.00	0.00	0.00	-

Sources: C4 Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: C4 Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on C4 Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.